Parkinson's disease is a disorder of dopaminergic neurotransmission, but its pharmacological management cannot be understood without recognizing that dopamine functions across four anatomically distinct CNS projection systems, each with its own behavioral and physiological role. The motor deficits that define the clinical syndrome reflect selective degeneration of one of these systems, while the non-motor features, the psychiatric complications of drug treatment, and the endocrine side effects of dopamine-blocking drugs each reflect the involvement of the others.

The nigrostriatal pathway is the dopaminergic system of primary relevance to Parkinson's disease (PD). Its cell bodies reside in the substantia nigra pars compacta (SNpc), a pigmented midbrain nucleus located in the ventral mesencephalon just dorsal to the cerebral peduncles. The neuromelanin that gives this nucleus its characteristic dark appearance is a byproduct of dopamine oxidative metabolism. Axons from the SNpc project rostrally through the medial forebrain bundle to terminate densely in the dorsal striatum, specifically in the caudate nucleus and, more extensively, in the putamen.¹ The putamen is the primary motor division of the striatum and receives its dopaminergic input from the SNpc in a topographically organized fashion, with the dorsolateral putamen receiving the most dense projection and being the region most severely depleted in PD.

The mesolimbic pathway originates from the ventral tegmental area (VTA), a cluster of dopaminergic neurons located medial and slightly rostral to the SNpc in the midbrain. VTA neurons project to the nucleus accumbens, olfactory tubercle, amygdala, and hippocampus, collectively comprising the ventral striatum and associated limbic structures.² This pathway is the principal substrate of reward, motivation, and reinforcement learning. Its relevance to PD pharmacology is direct: dopamine agonists used to treat PD act not only on the depleted nigrostriatal system but also on mesolimbic D3 receptors in the nucleus accumbens, which is the mechanistic basis of the impulse control disorders, including pathological gambling, hypersexuality, and compulsive eating, that can complicate dopamine agonist therapy.

The mesocortical pathway also originates from the VTA but projects to the prefrontal cortex, anterior cingulate cortex, and other frontal association areas. This system modulates working memory, cognitive flexibility, attention, and executive function.² Degeneration within this pathway, which occurs in more advanced PD particularly as disease spreads beyond the nigrostriatal system, contributes to the cognitive impairment and dementia seen in a substantial proportion of patients with long-standing disease. The mesocortical pathway is also central to the pharmacology of antipsychotic drugs: blockade of mesocortical D2 receptors is believed to contribute to the cognitive blunting seen with first-generation antipsychotics, while the drug-induced parkinsonism caused by those agents reflects their blockade of nigrostriatal D2 receptors.

The tuberoinfundibular pathway connects the arcuate nucleus and periventricular nucleus of the hypothalamus to the median eminence and anterior pituitary portal circulation. Dopamine released by this pathway acts as the primary physiological inhibitor of prolactin secretion from anterior pituitary lactotroph cells, suppressing prolactin release tonically under normal conditions.³ This pathway is largely intact in PD, which means dopamine replacement therapy does not significantly alter prolactin levels. However, dopamine antagonists, including antipsychotics and the antiemetic metoclopramide, block tuberoinfundibular D2 receptors and cause hyperprolactinemia, with clinical consequences including galactorrhea, amenorrhea, gynecomastia, and sexual dysfunction.

A precise understanding of dopamine biochemistry is not academic background for the Parkinson's pharmacologist; it is the direct mechanistic basis for every drug intervention in this chapter. The sites of synthesis, storage, release, and reuptake each represent therapeutic targets, and the enzymes of dopamine catabolism are the targets of two drug classes used in PD management.

Dopamine synthesis begins with the amino acid tyrosine, which is transported into dopaminergic neurons by the large neutral amino acid transporter (LAT1/LAT2). Tyrosine is hydroxylated to L-3,4-dihydroxyphenylalanine (levodopa, L-DOPA) by tyrosine hydroxylase (TH), the rate-limiting enzyme of the pathway. TH requires tetrahydrobiopterin as a cofactor and is subject to end-product inhibition by dopamine itself, providing negative feedback regulation of synthesis.⁶ Levodopa is then decarboxylated to dopamine by aromatic L-amino acid decarboxylase (AADC, also called DOPA decarboxylase), a pyridoxal phosphate-dependent enzyme that is expressed not only in dopaminergic neurons but also throughout the gastrointestinal tract and in peripheral tissues. This peripheral expression of AADC is the reason that oral levodopa must be co-administered with a peripheral AADC inhibitor: without it, the vast majority of levodopa is converted to dopamine in the gut wall and peripheral circulation before it can cross the blood-brain barrier.

Newly synthesized dopamine is packaged into synaptic vesicles by the vesicular monoamine transporter 2 (VMAT2), which uses the proton gradient across the vesicular membrane to concentrate dopamine against a steep concentration gradient. VMAT2 is the target of reserpine, which depletes all monoamines from vesicular stores, and tetrabenazine, which is used clinically to reduce dyskinesias in Huntington's disease by the same mechanism. In the dopaminergic terminal, vesicle docking and calcium-dependent exocytosis release dopamine into the synapse in response to action potentials.⁷ The extent of release is regulated by presynaptic D2 autoreceptors, which are located on the dopaminergic terminal itself and on the cell body in the substantia nigra. Activation of these autoreceptors by released dopamine reduces synthesis (by inhibiting TH) and reduces further release, providing a feedback brake on dopaminergic neurotransmission. D2 autoreceptors are clinically relevant because dopamine agonists acting at these sites can paradoxically reduce dopaminergic tone at lower doses, a phenomenon seen in the early dose-finding phase of agonist therapy.

Following release, dopamine is cleared from the synapse primarily by reuptake via the dopamine transporter (DAT), a sodium- and chloride-dependent member of the SLC6 family of neurotransmitter transporters. DAT is expressed on presynaptic dopaminergic terminals throughout the striatum and is the molecular target of cocaine and amphetamine. In the context of PD, DAT expression is reduced in proportion to the degree of nigrostriatal degeneration and is used clinically as a biomarker: DAT-SPECT imaging (DaTscan) demonstrates reduced striatal DAT binding in PD, distinguishing it from essential tremor in diagnostically ambiguous cases.⁸ Dopamine remaining in the synapse or taken up by non-neuronal cells is metabolized by two enzymatic pathways: monoamine oxidase B (MAO-B), located on the outer mitochondrial membrane of neurons and glial cells, and catechol-O-methyltransferase (COMT), located postsynaptically and in glial cells. MAO-B converts dopamine to DOPAC (3,4-dihydroxyphenylacetic acid), while COMT converts dopamine to 3-methoxytyramine. Both enzymes are therapeutic targets in PD: MAO-B inhibitors extend the duration of action of released dopamine, and COMT inhibitors reduce the peripheral and central methylation of levodopa, extending its plasma half-life and increasing its CNS availability.

Dopamine receptors are G protein-coupled receptors divided into two families based on their signal transduction mechanisms. The D1 family, comprising D1 and D5 receptors, couples through Gs/Golf proteins to stimulate adenylyl cyclase, increasing intracellular cyclic AMP. D1 receptors are expressed at high density on direct pathway striatal MSNs, on postsynaptic targets in the prefrontal cortex, and in the substantia nigra. D2 family receptors, comprising D2, D3, and D4 receptors, couple through Gi/Go proteins to inhibit adenylyl cyclase, reduce calcium channel conductance, and activate inward-rectifying potassium channels, collectively producing neuronal inhibition.⁹ D2 receptors are expressed on indirect pathway MSNs, on dopaminergic terminals and cell bodies as autoreceptors, and postsynaptically in the limbic system and cortex. D3 receptors are expressed preferentially in the nucleus accumbens and other limbic structures. Most dopamine agonists used in PD have preferential affinity for D2 and D3 receptors; their varying D3/D2 selectivity ratios contribute to differential propensities for impulse control disorders and orthostatic hypotension.

The clinical syndrome of Parkinson's disease encompasses far more than the motor triad of bradykinesia, rigidity, and tremor that appears in textbook definitions. The non-motor symptoms are often more disabling to patients than the motor features in mid-to-late disease, and several are the direct pharmacological targets of treatments distinct from dopamine replacement. A coherent understanding of PD management requires mapping each clinical feature to its neurochemical and anatomical substrate.

The cardinal motor features of PD are bradykinesia, rigidity, rest tremor, and postural instability, with bradykinesia being the defining feature required for diagnosis by current criteria. Bradykinesia refers to slowness of movement, with associated reduction in movement amplitude (hypokinesia) and decremental amplitude with repetitive movements. It is the most direct clinical expression of the basal ganglia circuit imbalance described in Section 2: reduced thalamocortical drive produces impairment in the initiation and scaling of voluntary movements.⁵ Rigidity is a velocity-independent increase in muscle tone present throughout the range of passive movement, often with a cogwheel quality due to superimposed tremor. Its mechanism involves abnormally increased tonic stretch reflex activity secondary to disordered basal ganglia modulation of spinal motor circuits. Rest tremor, typically at 4–6 Hz and most prominent in the distal upper extremity with a characteristic pill-rolling quality, is partially suppressible with voluntary movement and worsens with emotional stress or distraction. Postural instability, the impairment of righting reflexes that leads to falls, is a late feature that responds poorly to dopaminergic therapy and is associated with degeneration of non-dopaminergic systems including the pedunculopontine nucleus.

Non-motor symptoms of PD span neuropsychiatric, autonomic, sensory, and sleep domains, and their neurochemical substrates are correspondingly diverse. Depression and anxiety affect approximately 40–50% of patients and have a complex pathogenesis involving degeneration of noradrenergic neurons in the locus coeruleus and serotonergic neurons in the raphe nuclei, in addition to reactive psychological responses to a progressive neurological diagnosis.¹³ REM sleep behavior disorder (RBD), in which patients act out dreams due to loss of normal REM atonia, is one of the most specific prodromal markers of PD and related synucleinopathies; it reflects degeneration of brainstem structures regulating REM sleep atonia, particularly the sublaterodorsal nucleus and related pontine circuits. Anosmia, present in approximately 90% of PD patients and often preceding motor symptoms by years, reflects early olfactory bulb involvement in the Braak staging progression.

Autonomic dysfunction in PD is pervasive and arises from degeneration of both central autonomic control structures and peripheral autonomic neurons. The dorsal vagal nucleus, affected in early Braak stages, and sympathetic ganglionic neurons are both sites of alpha-synuclein pathology, contributing to a pattern of autonomic failure that includes orthostatic hypotension, constipation, urinary dysfunction, erectile impotence, and thermoregulatory disturbance.¹² Orthostatic hypotension in PD is particularly challenging to manage because dopaminergic drugs commonly used for motor symptoms can worsen it by their vasodilatory properties, creating a direct therapeutic conflict. Constipation, which affects the majority of patients and frequently predates motor symptoms, reflects alpha-synuclein pathology in the enteric nervous system and reduced colonic motility.

Cognitive impairment in PD ranges from mild executive dysfunction in early disease, reflecting mesocortical dopamine depletion and cholinergic denervation from the basal nucleus of Meynert, to frank dementia (Parkinson's disease dementia, PDD) in advanced disease, which ultimately affects over 80% of patients who survive long enough.¹⁵ PDD shares pathological features with dementia with Lewy bodies and is driven by cortical alpha-synuclein pathology and cholinergic denervation. The cholinergic deficit in PDD is at least as severe as in Alzheimer's disease, which is the basis for the use of the cholinesterase inhibitor rivastigmine, the only agent with regulatory approval for PDD. Psychosis in PD, manifesting as formed visual hallucinations and delusions, arises from an interaction of dopaminergic drug treatment, underlying Lewy body cortical pathology, and cholinergic denervation, and requires careful pharmacological management because most antipsychotics worsen motor function by blocking nigrostriatal D2 receptors.

Sensory symptoms, particularly pain and aching in the limbs, are reported by a substantial minority of patients and may precede motor diagnosis. These likely reflect basal ganglia modulation of sensory processing and dopaminergic effects on central pain pathways. Fatigue, one of the most common and disabling non-motor complaints, has a complex and incompletely understood basis involving both central dopaminergic and non-dopaminergic circuits. Hypersalivation and sialorrhea in PD result not from overproduction of saliva but from reduced swallowing frequency due to motor involvement of oropharyngeal musculature, a distinction that matters because treatment involves improving swallowing mechanics or reducing salivary gland output rather than treating a secretory excess. This symptom framework, mapping each clinical feature to its neurochemical and anatomical basis, provides the organizing structure for the drug-by-drug discussion that follows in subsequent modules.